EXPAREL is indicated for administration into the surgical site to produce postsurgical analgesia.
The product combines bupivacaine with DepoFoam, a product delivery technology that delivers medication over a desired time period.
Pacira president and CEO Dave Stack said: "For the millions of patients undergoing surgical procedures in the U.S. each year, the introduction of EXPAREL–a single-dose, non-opioid local analgesic given at the close of surgery–represents a significant addition to the armamentarium of currently available options to manage postsurgical pain."